

SUPPLEMENTAL TABLE OF CONTENTS

Greater risk of severe hyperparathyroidism requiring early parathyroidectomy after kidney transplantation in patients treated with etelcalcetide.

Supplemental Table 1. List of collaborative authors of the CUSL Kidney Transplantation Network	Page 2
Supplemental Table 2. Supplemental baseline characteristics.....	Page 3
Supplemental Table 3: Dose of etelcalcetide and occurrence of parathyroidectomy after kidney transplantation	Page 4
Supplemental Figure 1. Plasma calcium and iPTH levels at the time of parathyroidectomy in cinacalcet and etelcalcetide patients.....	Page 5
Supplemental Figure 2. New prescriptions of cinacalcet and etelcalcetide over the study period	Page 6

Supplemental Table 1. List of collaborative authors of the CUSL Kidney Transplantation Network

NAME	AFFILIATION
Pierre-Yves Declaire	Service de néphrologie, Clinique Sud Luxembourg, Arlon, Belgium
Marie Rommelaere	Service de néphrologie, Hôpital Princesse Fabiola, Aye, Belgium
Miguel-Ange Guillen	Service de néphrologie, CHR Epicura, Mons, Belgium
Benoit Buyschaert	Service de néphrologie, CHR de Huy, Huy, Belgium
Bénédicte Vanderperren	Service de néphrologie, Centre hospitalier de Jolimont, La Louvière, Belgium
Charles Cuvelier	Service de néphrologie, CHU UCL-Namur – Site Ste Elisabeth, Namur, Belgium
Benoît Georges	Service de néphrologie, CHR Sambre-Meuse (Namur), Namur, Belgium
Eugenia Papakrivopoulou	Service de néphrologie, Clinique Saint-Jean, Brussels, Belgium
Claude Braun	Service de néphrologie, Hôpitaux Roberts Schuman, Luxembourg, Luxembourg
Gaëlle Gillerot	Service de néphrologie, Clinique Saint-Pierre, Ottignies, Belgium
Jean-Philippe Lengelé	Service de néphrologie, Grand Hôpital de Charleroi, Charleroi, Belgium
François Reginster	Service de néphrologie, Cliniques de l'Europe, Brussels, Belgium
Philippe Leroy	Service de néphrologie, Hôpital de mons – Groupe Jolimont, Mons, Belgium
Ann-Karolien Vandooren	Service de néphrologie, CH de Mouscron, Mouscron, Belgium
Philippe Madhoun	Service de néphrologie, Centre Hospitalier de Wallonie picarde, Tournai, Belgium


Supplemental Table 2. Supplemental baseline characteristics

	Whole cohort n=372	No calcimimetic n=262	Cinacalcet n=75	Etelcalcetide n=35	<i>P</i>
Type of donor – no. (%)					0.02
Deceased	311 (84)	210 (80)	69 (92)	32 (91)	
Living	61 (16)	52 (20)	6 (8)	3 (9)	
Graft rank – no. (%)					0.035
1	330 (89)	238 (91)	60 (80)	33 (94)	
2	36 (10)	20 (8)	14 (19)	2 (6)	
3	5 (1)	4 (1)	1 (1)	0 (0)	
PRA, % (mean±SD)	19±32	17±31	22±34	24±36	0.29
HLA Mismatch (es) – no. (%)					0.826
0	27 (7)	15 (6)	9 (12)	3 (8,5)	
1	28 (8)	20 (7,5)	5 (6,6)	3 (8,5)	
2	94 (25)	66 (25)	20 (26,6)	8 (23)	
3	140 (38)	99 (38)	27 (36)	14 (40)	
4	40 (11)	29 (11)	6 (8)	5 (14)	
5	21 (5,5)	18 (7)	2 (2,7)	1 (3)	
6	5 (1)	3 (1)	2 (2,7)	0 (0)	
Missing	17 (4,5)	12 (4,5)	4 (5,3)	1 (3)	
Induction therapy – no. (%)	135 (36)	96 (36)	28 (37)	11 (31)	0.816

Supplemental Table 3. Dose of etelcalcetide and occurrence of parathyroidectomy after kidney transplantation.


	No PTX n=25	PTX n=10	P
Dose etelcalcetide (mg) – no. (%)			0.02
2.5	5 (20)	2 (20)	
5	13 (52)	2 (20)	
7.5	2 (8)	0 (0)	
10	5 (20)	2 (20)	
15	0 (0)	4 (40)	

Supplemental Figure 1. Plasma calcium and iPTH levels at the time of parathyroidectomy in cinacalcet and etelcalcetide patients.



	Cinacalcet (n=9)	Etelcalcetide (n=10)
25% Percentile	2.645	2.760
Median	2.730	2.870
75% Percentile	2.815	2.965


P-value = 0.03 (Mann-Whitney)



	Cinacalcet (n=9)	Etelcalcetide (n=10)
25% Percentile	112.0	186.0
Median	194.0	243.5
75% Percentile	368.0	506.8

P-value = 0.34 (Mann-Whitney)

Supplemental Figure 2. New prescriptions of cinacalcet and etelcalcetide over the study period. Etelcalcetide became commercially available in Belgium in 2018.



One patient was receiving etelcalcetide in 2013 during participation to the phase 3 trial and its extension.